Predictive lab models of human digestion and absorptionAelius Biotech specialise in lab models of the aerodigestive tract. Our predictive systems can help you understand your formulation during vital pre-clinical stages to help you improve and de-risk product development and get succesful products to market.
What We Do
Aelius Biotech is a contract research company specialising in modelling the aero-digestive tract without the use of animal testing. Our Integrated Model Gut System is a lab model stretching from the mouth to the large intestine capable of modelling digestion, mucus permeation and absorption. We also have expertise in modelling other mucosal surfaces incuding the airways and access to a range of analytical services for specialised testing.
Test efficacy, refine formulations, develop mechanistic data for EFSA submissions, predict and design human trials.
From whole meals to single substrates our systems can model how your performs in a physiologically relevant simulation of digestion.
Through close collaboration with Newcastle University we are able to offer human trials for acceptability, palatability and efficacy from pilot to large scale.
Using a unique method for combining mucus with cell culture models allows us to simulate dissolution, mucus permeation and epithelial absorption in a single system.
The mucus barrier acts as a key barrier to intestinal absorption. Failure to appreciate this often leads to problems with drug delivery. Our systems can simulate and predict mucus permeation.
We offer competitive pricing and high quality service delivery for routine analysis and testing, along with involved follow up to help understand and interpret results.
Aelius Biotech systems are flexible and our scientists enjoy a challenge so if you have a sticky problem with mucus or the digestive tract, please get in touch.
Aelius Biotech have access to a range of standard cell lines as well as primary cell cultures from patients and normals for absorption studies.
Get in touch to see how our team of academic and industry experts can help you.
Hear from some of our previous customers how Aelius Biotech services have been able to help with product development:
Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems
Chater, Peter I., Matthew D. Wilcox, and Jeffrey P. Pearson. Advanced drug delivery reviews (2017).
ζ potential changing nanoparticles as cystic fibrosis transmembrane conductance regulator gene delivery system: an in vitro evaluation.
Prüfert, Felix, Sonja Bonengel, Saskia Köllner, Janine Griesser, Matthew D. Wilcox, Peter I. Chater, Jeffrey P. Pearson, and Andreas Bernkop-Schnürch. Nanomedicine 12, no. 22 (2017): 2713-2724.
The properties of the mucus barrier, a unique gel–how can nanoparticles cross it?.
Pearson, Jeffrey P., Peter I. Chater, and Matthew D. Wilcox. Therapeutic delivery 7, no. 4 (2016): 229-244.
The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine.
Wilcox, M. D., L. K. Van Rooij, P. I. Chater, I. Pereira de Sousa, and J. P. Pearson. European Journal of Pharmaceutics and Biopharmaceutics 96 (2015): 484-487.
Ask an AELIUS expert how we can help you:
Understand our integrated in vitro gastrointestinal model of digestion and absorption and its relevant applications or Learn more about our innovative mucus gels suitable for modelling mucosal surfaces of the body in the lab without the need for animal models.
Write to us at email@example.com
Nice to meet you
CEO. Peter Chater is an Innovation Fellow at Newcastle University who works on in vitro modelling of the digestive tract.
Chief Scientific Officer. Jeff Pearson is a professor of molecular physiology with over 30 years of experience in gastrointestinal physiology.
Chairman. Peter Dettmar has over thirty years’ experience of the pharmaceutical industry, leading gastrointestinal R&D and is a named inventor on over 40 patents.
Finance Director. Harvey Dettmar has a background in technology and investment banking and has created and worked for a number of healthcare start-up companies in finance, operations and sales.
COO. Matt has over 10 years experience in modelling digestion at Newcastle University where he has also set up and run numerous human trials.
Development Scientist. Kyle works on developing the modelling capabilities of Aelius Biotech.
Get in touch
AELIUS BIOTECH is a leading innovator in modelling human digestive physiology. Our technology is a unique tool for the study of drug delivery, nutrient break down and gut biology. Get in touch for more information
ICAMB, Cookson Building, Newcastle
University, Framlington Road,
Newcastle upon Tyne NE2 4HH
0191 208 5013